Vimarsana
Biggest News Aggregation in the World

Edo Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Edo Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Edo Development Today - Breaking & Trending Today

India, Greece Strengthen Strategic Partnership In Defence - Vimarsana News

India, Greece Strengthen Strategic Partnership In Defence

India and Greece are strengthening their strategic partnership, particularly focusing on enhancing defence cooperation through co-production and co-development initiatives.

'Fireman Sam' and 'Polly Pocket' Get New Season Greenlights from WildBrain and Mattel - Vimarsana News

'Fireman Sam' and 'Polly Pocket' Get New Season Greenlights from WildBrain and Mattel

International distribution deals were also announced for new and previous seasons of the popular animated series as well as ‘Bob the Builder’ and ‘Little People;’ WildBrain is heading to MIPCOM, which runs October 16-19.

Source: awn.com
Sixteen South and Nelvana Option 'A Horse Named Steve' | Animation World Network - Vimarsana News

Sixteen South and Nelvana Option 'A Horse Named Steve' | Animation World Network

Belfast-based studio teams up with kids’ content giant on an animated adaptation of Toronto author-illustrator Kelly Collier’s popular picture book about the humorous exploits of an endearingly self-absorbed horse.

Source: awn.com
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA (pembrolizumab) - Vimarsana News

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA (pembrolizumab)

DAEJEON,South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy. Under the terms of the agreement, PharmAbcine will sponsor a Phase I s...

MLILY USA Begins Co-Development of New Products with ICA Partners - Vimarsana News

MLILY USA Begins Co-Development of New Products with ICA Partners

Furniture Industry News: International Chiropractors Assn. visit to flagship factory kicks off collaboration to design mattresses and pillows for back and sleep health.